


SUPPLEMENTARY INFORMATION:

Myelo-lymphoid lineage restriction occurs in the human haematopoietic stem cell compartment before lymphoid-primed multipotent progenitors

Belluschi et al.




Supplementary Figure 1: Sorting strategies and analysis of single cell derived colonies.

a, Representative example of gating strategy used to isolate HSC/MPPs (Fig. 1a-c, Fig. 1h, Fig. 2a), 49f⁺ HSCs (Fig. 1d-g, Fig. 1i-k, Fig. 2a, Fig. 3a-b, Fig. 4a) and 49f⁻ HSCs from

CD34⁺ CB cells. 49f⁺ HSCs are defined as the highest 30% CD90⁺ CD49f⁺, and 49f⁻ HSCs as the lowest 30% CD90⁻ CD49f⁻ ¹. **b**, Representative example of CLEC9A cell surface expression in CB 49f⁺ HSCs (top left, count=307 cells) and 49f⁻ HSCs (top right, count=296 cells). Percentage of CLEC9A⁺ cells in the indicated populations (lower panel). **p<0.01, ***p<0.001 by one-way ANOVA with Tukey's multiple comparison. Mean ± SEM is shown. **c**, Clonogenic efficiency of single HSC/MPP pool cells (n=537 single cells plated from 6 independent CBs; top panel) and single 49f⁺ HSCs (n=1104 single cells plated from 4 independent CBs; bottom panel) in the single cell differentiation assay. Mean ± SEM is shown. **d**, Gating strategy used for lineage determination of colonies derived from HSC/MPP pool or 49f⁺ HSC single cells. Erythroid colonies were identified as GlyA⁺≥30 cells, megakaryocytic colonies as CD41⁺≥30 cells, myeloid colonies as [(CD45⁺ CD14⁺) + (CD45⁺ CD15⁺)]≥30 cells, NK colonies as CD45⁺ CD56⁺≥30 cells. Two representative examples (one My/NK and one Ery/Meg colony) are shown. This gating strategy was used for [Fig. 1a-h](#), [Fig. 2b-e](#), [Fig. 4c](#). **e**, Percentage of My colonies of the indicated type MonoGran, Mono, Gran and undetermined (-) derived from HSC/MPP pool single cells (n=362 colonies from 6 independent CBs) and 49f⁺ HSCs (n=725 colonies from 4 independent CBs); Mean ± SEM is shown. **f**, **g**, Principal Component Analysis (PCA) of cell surface marker expression at the time of sort of single HSC/MPP pool cells isolated from 6 independent CBs (**f**) and single 49f⁺ HSCs isolated from 4 independent CBs (**g**) that produced My colonies (**f**, n=158 cells, **g**, n=309 cells). Density plots (top panel) and boxplots (bottom panel) of PC1. **h**, Representative example of non-linear fit of cumulative first division kinetics for single 49f⁺ HSCs producing colonies containing one of the two indicated lineages (Ery n=91, NK n=139); ***p<0.001 by extra sum-of-square F test. **i**, Size of different types of colonies (number of cells) derived from 49f⁺ HSC single cells from 4 independent CBs. **p<0.01, ***p<0.001 by Kruskal-


Wallis test with multiple comparison. All boxplots show median, interquartile and 5-95 percentile.



Supplementary Figure 2: Expression of CLEC9A and CD34 polarises the 49f⁺ HSC compartment

a, Normalised intensity of CLEC9A and CD34 expression at the time of the sort for 49f⁺ single cells which produced the indicated colonies. n=714 colonies from 4 independent CBs. Median fluorescence intensity shift between My/Ery and My/NK: CLEC9A: 40% and CD34:


13%. ** $p < 0.01$ by Kruskal-Wallis test with multiple comparison. **b**, Normalised intensity of CLEC9A and CD34 expression at the time of the sort for $49f^+$ HSC single cells which produced the indicated colonies. My/NK colonies are defined My-biased if number of My cells $>$ number of Ly (NK) cells within that colony and Ly-biased if number of My cells $<$ number of Ly cells. Similarly, in Ery-biased My/Ery colonies, the number of My cells $<$ number of Ery cells. (n=93 My/Ery colonies and n=170 My/Ly colonies from 4 independent CBs). Median fluorescence intensity shifts: between My/NK: My-biased and My/NK: Ly-biased: CLEC9A: 25%; CD34: 4%; between My/Ery: My-biased and My/Ery: Ery-biased: CD34: 4%. * $p < 0.05$ *** $p < 0.001$ by two-sided unpaired t-test. All boxplots show median, interquartile and 5-95 percentile. **c**, CLEC9A cell surface marker expression overlaid on 3D PCA (**c**) or diffusion map (**d**) representation of $49f^+$ HSCs. **e**, **f**, CD34 cell surface marker expression overlaid on 3D PCA (**e**) or diffusion map (**f**) representation of $49f^+$ HSCs. **g**, Heatmap of expression of guide genes selected by ICGS algorithm performed on $49f^+$ HSCs. Rows represent genes and columns single cells. Top panel bar shows major clusters identified by ICGS. **c-g**: n=169 single cells that passed quality control.



Supplementary Figure 3: Characterisation of Subset1, Subset2, 49f⁺ Subset1 and 49f⁺ Subset2 populations.

a, b, Clonogenic efficiency of Subset1 and Subset2 cells (n=4 independent CBs, total 336 cells plated per subset, minimum 72 cells per CB) (**a**), 49f⁺ Subset1 and 49f⁺ Subset2 cells (n= 5 independent CBS, 714 total cells plated for 49f⁺ Subset1 and 756 for 49f⁺ Subset2, minimum 54 cells per CB, *p<0.05 by two-sided paired t-test) (**b**) in the same single cell differentiation assay as in Fig. 1 a-d. **c, d,** Percentage of My colonies of the type MonoGran, Mono, Gran and undetermined (-) derived from Subset1 (n=194) and Subset2 (n=114) (**c**), 49f⁺ Subset1 (n=550) and 49f⁺ Subset2 (n=450) (**d**) single cells from 4 (Subset1, Subset2)


and 5 (49f⁺ Subset1, 49f⁺ Subset2) independent CBs; *p<0.05, **p<0.01, ***p<0.001 by two-sided unpaired t-test. **e**, Clonogenic efficiency of Subset1 and Subset2 cells (n=3 independent CBs, total 174 cells plated per subset, minimum 27 cells per CB) in the single cell assay allowing for growth of B, NK and My cells. **f**, Percentage of CD71⁺GlyA⁺ erythroblasts obtained at day 7, 12 and 16 by RBC assay after plating 1500 Subset1 and Subset2 cells (left), and 350-1200 cells 49f⁺ Subset1 and 49f⁺ Subset2 (right, n=2); n=2 independent CBs; *p<0.05 by 2-way ANOVA with Sidak's multiple comparisons. **a-f**, mean \pm SEM is shown. **g**, Number of colonies/100 cells from either Subset1 or Subset2 populations sorted using alternative CD34 and CLEC9A antibody clones and/or fluorochrome combinations (Antibody panel I, see methods) and plated in CFU assay. Colony types: Ery (E), granulocyte and My (GM) or a combination of both (mix) is shown, (n=1 CB).



Supplementary Figure 4: Transcriptional landscapes of 49f⁺ HSCs and Subset1 and Subset2 cells

a-d, Single-cell RNA-seq analysis of 49f⁺ HSCs (n=169), 49f⁺ Subset1 (n=78) and 49f⁺ Subset2 (n=75) single cells. **a**, Density plots of the distribution of single 49f⁺ HSCs (grey), 49f⁺ Subset1 (red) and 49f⁺ Subset2 (blue) cells along the indicated tSNE components. $p < 0.001$ by two-tailed unpaired t-test comparing 49f⁺ Subset1 and 49f⁺ Subset2. **b**, **c**, 3D PCA (**b**) and diffusion map (**c**) representation of single 49f⁺ HSCs (grey), 49f⁺ Subset1 (red) and 49f⁺ Subset2 (blue) cells. All PCA and diffusion map analyses were performed on highly variable genes (2420 genes computed as in ²). **d**, Log₁₀ normalised expression of CLEC9A


(left) and CD34 (right) from 78 49f⁺ Subset1 single cells and 75 49f⁺ Subset2 single cells as measured by single cell RNA-seq. **e**, Cell surface expression of CLEC9A (left) and CD34 (right) for the same single cells shown in a as measured by index sorting. **f**, ICGS analysis: cell surface expression levels of CLEC9A (left panel) and CD34 (right panel) in 49f⁺ HSCs of the indicated ICGS clusters (excluding 49f⁺ Subset1 and 49f⁺ Subset2 cells); *p<0.05, **p<0.01, ***p<0.001 by one-way ANOVA with Bonferroni correction for multiple comparisons. Boxplots show median, interquartile and 5-95 percentile. **g**, Hierarchical clustering of highly variable genes of 20-cell samples of Subset1 and Subset2 cells; shown is 1-Pearson correlation; Subset1: n=7; Subset2: n=6 independent 20-cell samples.



Supplementary Figure 5: Comparison of 49f⁺ Subset1 and 49f⁺ Subset2 *in vitro* derived populations.

a, Clonogenic efficiency (calculated as number of colonies/number of seeded cells) of the indicated day 5 populations; mean \pm SEM is shown. n=576 cells plated from 3 independent CBs for 49f⁺ Subset1 derived populations, n=576 cells plated from 3 independent CBs for 49f⁺ Subset2 derived populations; *p<0.05, **p<0.01 by one way-ANOVA with Tukey's multiple comparison. **b**, CD45RA cell surface intensities for single cells from Diff1 and Diff2 populations (gated as in Fig. 4b) from one representative experiment. **c**, Size of colonies (number of cells) generated by single cells from the indicated 49f⁺ Subset1 and 49f⁺ Subset2 derived populations. ***p<0.001 by multiple comparison Kruskal-Wallis test. Boxplots show median, interquartile and 5-95 percentile. **d**, Percentage of My colonies of the MonoGran, Mono, Gran and undetermined types derived from S1_1 (n=159), S2_1 (n=103) and


Diff1(n=72); S2_2 (n=62) and Diff2 (n=22) single cells from 3 independent CBs; mean \pm SEM is shown.



Supplementary Figure 6: Differentiation capacity of Subset1 and Subset2 cells *in vivo*.

a, Representative example of the gating strategy used to assess lineage potential *in vivo*. Ery cells were identified as CD45⁻GlyA⁺, B cells as CD45⁺⁺CD19⁺⁺ and myeloid cells as CD45⁺⁺CD33⁺. To avoid false positives a double staining for CD45 and CD19 was

performed using two different antibodies for each marker (Antibody panel F or G, see methods). Examples of two multi-lineage (My/Ly/Ery) engrafted mice (top and middle) and one My/Ly engrafted mouse (bottom) are shown. These gates were used for the results in [Fig. 5. b](#), Percentage of phenotypic 49f⁺ HSCs within Subset1 and Subset2 (n=5 independent CBs), mean \pm SEM is shown. **c**, Relative Ly (left), My (middle) and Ery (right) engraftment (percentage of total human grafted cells) as a function of human engraftment (percentage of CD45⁺ and GlyA⁺ present in the injected bone of each transplanted mouse). Subset1: n=27 mice; Subset2: n=12 mice; 49f⁺ Subset1: n=19 mice; 49f⁺ Subset2: n=3 mice. Of note, 13/15 animals engrafted with Subset1 at >1% produced Ery cells, while 0/3 animals transplanted with Subset2 did (p=0.012 by two-tailed Fisher test). **d**, Percentage of human engraftment (% CD45⁺ + GlyA⁺) in the injected femur of secondary transplantation recipients injected with CD34⁺CD38⁻ cells isolated from primary mice engrafted with Subset1 (n=9, red) and Subset2 (n=2, blue) cells (see Fig. 5 for primary transplantation data). Dashed line: threshold of engraftment ((%CD45⁺ + %GlyA⁺) \geq 0.01% and at least 30 cells recorded. Non-engrafted mice are shown below the dashed line.



Supplementary Figure 7: Cell surface markers expression differences between LMPPs and Subset2 cells

a, Representative sorting strategy used to isolate LMPPs and MLPs progenitors at day 0 from CD34⁺ CB cells. This strategy was used for experiments in Fig. 6. **b-d**, Cell surface marker expression comparison of CD34 (**b**), CLEC9A (**c**) and CD45RA (**d**) in 49f⁺ HSCs, Subset2 cells and LMPPs. A representative example of the expression of each marker in Subset2 cells and LMPPs is shown on the left. Bar graphs showing the Median Fluorescent Intensity (MFI) of each marker for 49f⁺ HSCs, Subset2 and LMPPs are shown on the right (n=3 independent CBs, mean ± SEM is shown, *p<0.05, **p<0.01, ***p<0.001 by one-way ANOVA with Tukey's multiple comparison).

Supplementary Table 1: *In vivo* limiting dilution assay of Subset1, Subset2, 49f⁺ Subset1 and 49f⁺ Subset2.

Weeks	Group	Dose	Engrafted/Injected Mice	Repopulating capacity			p-value
				lower	estimate	upper	
2	Subset 1	100	0/5	4334	1402	454	0.639
		500	3/9				
	Subset 2	100	0/5	2606	979	368	
		500	4/9				
8	Subset 1	100	1/3	780	296	113	0.077
		500	4/5				
	Subset 2	100	1/3	5209	1242	296	
		500	1/5				
20	Subset 1	50	4/8	1213	453	170	4.36x10 ⁻⁴
		250	5/6				
		3000	10/11				
	Subset 2	50	0/4	6379	2684	1129	
		250	2/9				
		3000	4/7				
20	49f ⁺ Subset 1	10	4/8	30.0	13.5	6.24	1.06x10 ⁻¹⁰
		50	5/5				
		200	10/10				
	49f ⁺ Subset 2	10	0/4	2143.1	685.5	219.5	
		50	1/9				
		200	2/9				

p-value was calculated via the ELDA method³

SUPPLEMENTARY REFERENCES

1. Notta, F. *et al.* Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. *Science* **333**, 218–221 (2011).
2. Brennecke, P. *et al.* Accounting for technical noise in single-cell RNA-seq experiments. *Nat. Methods* **10**, 1093–1095 (2013).
3. Hu, Y. & Smyth, G. K. ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. *J. Immunol. Methods* **347**, 70–78 (2009).